Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 206

Sort by

Sort Order Select

Journal Articles

Differing Perceptions between Myelodysplastic Syndrome (MDS) Patients and Providers Regarding Blood Transfusions

David J. King, BS, Martina C. Murphy, MD, Rodney A. Schmidt, PhD, Matthew Lesser, MS, Alice Houk, MPS, Ellen Salkeld, PhD, Christopher R. Cogle, MD

Blood (2019) 134 (Supplement_1): 5418.

https://doi.org/10.1182/blood-2019-123474

Published: 2019

Journal Articles

Evaluating Mean Corpuscular Volume As Predictor for Erythropoiesis Stimulating Agent Response in Elderly Patients Diagnosed with Myelodysplasia

Joshua P Muniz, MD, Sarvari Venkata Yellapragada, MD, Gustavo A. Rivero, MD

Blood (2019) 134 (Supplement_1): 5420.

https://doi.org/10.1182/blood-2019-131458

Published: 2019

Journal Articles

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Kristen M Corrao, MD, Alexandra M. Harrington, MDMT(ASCP), Steven H. Kroft, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5430.

https://doi.org/10.1182/blood-2019-130511

Published: 2019

Journal Articles

A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

Emily Bryer, DO, Michael Kallan, MS, Ting-Shaun Chiu, MS, Katerina Scheuba, David H. Henry, MD

Blood (2019) 134 (Supplement_1): 4944.

https://doi.org/10.1182/blood-2019-129316

Published: 2019

Journal Articles

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Blood (2019) 134 (Supplement_1): 5296.

https://doi.org/10.1182/blood-2019-121997

Published: 2019

Journal Articles

Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes

Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Eric Padron, MD, David A Sallman, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4177.

https://doi.org/10.1182/blood-2019-123536

Published: 2019

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Crystal Watson, MS, Arie Barlev, PharmD, Jodie Worrall, Steve Duff, MS, Rachel Beckerman, PhD

Blood (2019) 134 (Supplement_1): 5826.

https://doi.org/10.1182/blood-2019-122611

Published: 2019

Journal Articles

Analysis of the Eligibility of Patients with Sickle Cell Disease for Palliative Care

Pedro de Oliveira Toro da Silva, Cristina Bueno Terzi, MD PhD, Antonio Luis Eiras Falcão, MD PhD, Sara T Olalla Saad, PhD, Fernando Ferreira Costa, MD PhD, Paula De Melo Campos, MD

Blood (2019) 134 (Supplement_1): 4681.

https://doi.org/10.1182/blood-2019-128884

Published: 2019

Journal Articles

Low-Dose Epo after Tgfβ Blockade Triggers Robust Erythropoiesis and Increased RBC Production

Silvana Di Giandomenico, PhD, Ghaith Abu Zeinah, MD, Pouneh Kermani, PhD, Mia Yabut, BS, Thomas Stephens, BS, Nassima Messali, PhD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 2217.

https://doi.org/10.1182/blood-2019-129044

Published: 2019

Journal Articles

Augmenting the Patient Experience: Therapeutic Arts Interventions for Patients Undergoing Chemotherapy/Infusion

Fred Schiffman, MD, Cynthia S Peng, BS, Anna C Delamerced, BA, Lauren V Ready, MPH, Kevin S Tang, BA, Pamela Yan, BS, Laura L Butterfield, BSN, Alexandra Krupa, RN BSN ACM

Blood (2019) 134 (Supplement_1): 2187.

https://doi.org/10.1182/blood-2019-125265

Published: 2019

Journal Articles

Moral Distress, Anxiety, and Others Physical Symptoms Related to Hematopoietic Stem Cell Donation

Cesar Homero Gutierrez-Aguirre, PhD, Olga Graciela Cantu Rodriguez, MD, Fernando De la Garza-Salazar, MD, Rosario Salazar Riojas, Chem., Andres Gomez De Leon, MD, Perla R. Colunga Pedraza, MD, Geraldina Guerrero-González, PhD, Jose Carlos Jaime, MD PhD, Guillermo J. Ruiz-Arguelles, FRCP, MACP, David Gomez-Almaguer, MD, Oscar Gonzalez Llano, MD, Consuelo Mancias, MD

Blood (2019) 134 (Supplement_1): 1967.

https://doi.org/10.1182/blood-2019-131791

Published: 2019

Journal Articles

Real-World Treatment Patterns and Transfusion Burden Among US Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS)

Sudipto Mukherjee, MD PhD MPH, S. Lane Slabaugh, Ronda Copher, Jonathan Johnson, Paul Buzinec, Elizabeth S. Mearns

Blood (2019) 134 (Supplement_1): 3499.

https://doi.org/10.1182/blood-2019-123425

Published: 2019

Journal Articles

Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlled Study (IRON CLAD)

Jeffrey A. Gilreath, PharmD, Tamta Makharadze, MD, Ralph V. Boccia, MD, Anna Krupa, PharmD, David H. Henry, MD

Blood (2019) 134 (Supplement_1): 3535.

https://doi.org/10.1182/blood-2019-132135

Published: 2019

Journal Articles

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2019) 134 (Supplement_1): 4248.

https://doi.org/10.1182/blood-2019-127435

Published: 2019

Journal Articles

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

Miguel R. Abboud, MD, Jo Howard, MB, BChir, Rodolfo Cançado, Wally R Smith, MD, Birol Güvenç, MD, Noemi Espurz, Marine Weill, Mariane de Montalembert, MD PhD

Blood (2019) 134 (Supplement_1): 998.

https://doi.org/10.1182/blood-2019-125775

Published: 2019

Journal Articles

Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 841.

https://doi.org/10.1182/blood-2019-123064

Published: 2019

Journal Articles

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

David H. Henry, MD, John Glaspy, MD MPH, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, Moshe Mittelman, MD, Amy Zhou, MD, Charles Bradley, PhD, Gopal Saha, MD, Pamela Bartels, Leong Robert, Kin-Hung P Yu, MD

Blood (2019) 134 (Supplement_1): 843.

https://doi.org/10.1182/blood-2019-128714

Published: 2019

Journal Articles

Treatment of MDS

Uwe Platzbecker

Blood (2019) 133 (10): 1096–1107.

https://doi.org/10.1182/blood-2018-10-844696

Published: 2019

Journal Articles

Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis

Domenico Penna, MD, Natasha Szuber, MD, Terra L. Lasho, PhD, Christy Finke, BS, Rangit Reddy Vallapureddy, MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4300.

https://doi.org/10.1182/blood-2018-99-119910

Published: 2018

NARROW

Differing Perceptions between Myelodysplastic Syndrome (MDS) Patients and Providers Regarding Blood Transfusions

Evaluating Mean Corpuscular Volume As Predictor for Erythropoiesis Stimulating Agent Response in Elderly Patients Diagnosed with Myelodysplasia

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Analysis of the Eligibility of Patients with Sickle Cell Disease for Palliative Care

Low-Dose Epo after Tgfβ Blockade Triggers Robust Erythropoiesis and Increased RBC Production

Augmenting the Patient Experience: Therapeutic Arts Interventions for Patients Undergoing Chemotherapy/Infusion

Moral Distress, Anxiety, and Others Physical Symptoms Related to Hematopoietic Stem Cell Donation

Real-World Treatment Patterns and Transfusion Burden Among US Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS)

Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlled Study (IRON CLAD)

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)

Treatment of MDS

Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only